Recordati S.p.A. stock (IT0003828271): valuation metrics in focus after latest price moves on Borsa Italiana

Recordati S.p.A. shares remain in focus on Borsa Italiana as investors assess the Italian pharma group's latest price level against earnings multiples and dividend yield ahead of the weekend.

Recordati S.p.A. shares continue to attract attention on Borsa Italiana as investors look at the current price level in relation to the Italian pharma group's earnings profile and dividend yield heading into the weekend. According to Borsa Italiana data, the stock recently traded in the area of EUR 50 per share in Milan, keeping the company firmly within the FTSE MIB universe as one of Italy's notable healthcare names.

As a domestically headquartered pharmaceutical company with its primary listing in Italy, Recordati remains closely watched by investors on Borsa Italiana, where trading in euros reflects sentiment toward the country's broader healthcare segment. The stock is also followed on German platforms, where it is quoted in euros on venues such as gettex and Tradegate for investors accessing the Italian name via secondary listings in Germany.

In addition to day-to-day price moves, investors in Recordati often monitor valuation metrics such as the price-to-earnings ratio, the relationship between enterprise value and EBITDA, and the stock's dividend yield. These indicators are primarily derived from the group's reported financial statements and market capitalization as reflected on Borsa Italiana and summarized by financial data providers covering the Italian equity market.

As of: 05/06/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Recordati
• Sector/industry: Pharmaceuticals
• Headquarters/country: Milan, Italy
• Core markets: Europe, United States, selected emerging markets
• Key revenue drivers: Prescription pharmaceuticals, specialty and rare disease treatments
• Home exchange/listing venue: Borsa Italiana (REC)
• Trading currency: EUR

Recordati S.p.A.: core business model

Recordati focuses on researching, manufacturing and marketing prescription medicines and specialty treatments, with a particular emphasis on primary care and rare diseases that drive much of its revenue across Europe and other international markets.

Valuation metrics and multiples for Recordati S.p.A.

Investors assessing Recordati on Borsa Italiana typically look at classic valuation metrics to benchmark the share price against the group's underlying profitability and cash generation. Data services that track Italian blue chips, including members of the FTSE MIB, commonly report Recordati's price-to-earnings ratio based on the last 12 months of earnings per share, alongside enterprise value to EBITDA and the stock's dividend yield derived from the most recent annual distribution.

Market observers use these ratios to compare Recordati with other European pharmaceutical companies, taking into account factors such as the stability of cash flows from primary care products and the growth potential of its rare disease portfolio. The combination of recurring income from established therapies and investment in higher-margin specialty treatments plays a central role in how valuation multiples for the stock are interpreted within the broader healthcare sector.

Conclusion

Recordati S.p.A. remains a closely tracked Italian pharmaceutical stock on Borsa Italiana, with investors weighing its euro-denominated share price against earnings power and cash returns. The focus on valuation metrics such as earnings multiples and dividend yield helps market participants frame the risk-reward profile of the company within the broader European healthcare landscape. How these indicators evolve alongside the group's strategic execution and product pipeline will likely continue to shape sentiment toward the stock.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.